Role of taxanes in adjuvant therapy

Cancer Investigation

Volumn 18, Issue 1, 2000, Pages 32-38

  Münster, Pamela N ^a   Hudis, Clifford A ^a,b  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ANEMIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0343114394     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009023060     Document Type: Review

References (32)

1. Roberts JR, Rowinsky EK, Donehower RC, et al: Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells. J Histochem Cytochem 37:1659-1665, 1989.
2. Rowinsky EK, Donehower RC, Jones RJ, et al: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093-4100, 1988.
3. Pazdur R, Kudelka AP, Kavanagh JJ, et al: The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386, 1993.
4. Von Hoff DD: The taxoids: same roots, different drugs. Semin Oncol 24:S13-3-S13-10, 1997.
5. Hudis C, Riccio L, Holmes F, et al: Phase II study of semisynthetic paclitaxel in metastatic breast cancer. Eur J Cancer 33: 2198-2202, 1997.
6. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990.
7. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995.
8. Ravdin PM, Burris HA 3rd, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
9. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995.
10. Hudis CA, Seidman AD, Crown JP, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996.
11. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1994.
12. Valero V: Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology 11:34-36, 1997.
13. Fumoleau P, Fety R, Delecroix, V, et al: Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology 11: 29-31, 1997.
14. Burns HA 3rd: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology 11:50-52, 1997.
15. Perloff M, Norton L, Korzun AH, et al: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol 14:1589-1598, 1996.
16. Bonadonna G. Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547, 1995.
17. Hudis CA, Fournier M, Riccio L, et al: Five-year results of dose-intensive sequential adjuvant chemotherapy for women with high risk node-positive breast cancer: a phase II study. J Clin Oncol (in press).
18. Hudis C, Riccio L, Seidman A, et al: Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest 16:67-71, 1998.
19. Hudis C, Seidman A, Baselga J. et al: Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 17:93-100, 1999.
20. Demetri GD, Berry D, Norton L, et al: Clinical outcomes of nodepositive breast cancer patients treated with dose-intensified adriamycin/cyclophosphamide (AC) followed by Taxol (T) as adjuvant systemic chemotherapy (CALGB 9141 ). Proc Am Sot Clin Oncol 16:A503, 1997.
21. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997.
22. Wolmark N, Fisher B, Anderson S: The effect of increasing intensity and cumulative dose of adjuvant cyclophospamide in node-positive breast cancer. Breast Cancer Res Treat 46: A16, 1997.
23. Henderson IC, Berry D, Demetri G, et al: Improved disease-free and overall Survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer (BC). Proc Am Soc Clin Onc 17:A390, 1998.
24. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc Am Soc Clin Onc 17: A388, 1998.
25. Hudis C, Seidman A, Baodga J, et al: Sequential dose-dense doxorubicin, paclitaxel and cyclophosphamide for resectable breast cancer: feasibility and efficacy. J Clin Oncol 17:93-100, 1999.
26. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
27. Dombernowsky P, Gehl J, Boesgaard M, et al: Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 22:13-17, 1995.
28. Sledge GW Jr: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 22:123-125; discussion 126-129, 1995.
29. Sledge G Jr, Neuberg D, Ingle JN, et al: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Am Soc Clin Onc 16:A2, 1997.
30. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11:15-18, 1997.
31. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin TM (humanized Anti-HER2 antibody) to first line chemotherapy for HER 2 overexoression metastatic breast cancer (HER2+/ MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc AM Soc Clin Oncol 17: A377, 1998.
32. Hudis C, Riccio L, Seidman A, et al: Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest 16:67-71, 1998.